We are live on ! Find out more
GILD icon

Gilead Sciences

1,263 hedge funds and large institutions have $116B invested in Gilead Sciences in 2014 Q2 according to their latest regulatory filings, with 163 funds opening new positions, 527 increasing their positions, 461 reducing their positions, and 83 closing their positions.

New
Increased
Maintained
Reduced
Closed

96% more first-time investments, than exits

New positions opened: 163 | Existing positions closed: 83

46% more funds holding in top 10

Funds holding in top 10: 112164 (+52)

14% more repeat investments, than reductions

Existing positions increased: 527 | Existing positions reduced: 461

6% more funds holding

Funds holding: 1,1891,263 (+74)

0% less capital invested

Capital invested by funds: $116B → $116B (-$569M)

24% less call options, than puts

Call options by funds: $2B | Put options by funds: $2.62B

Holders
1,263
Holders Change
+74
Holders Change %
+6.22%
% of All Funds
36.28%
Holding in Top 10
164
Holding in Top 10 Change
+52
Holding in Top 10 Change %
+46.43%
% of All Funds
4.71%
New
163
Increased
527
Reduced
461
Closed
83
Calls
$2B
Puts
$2.62B
Net Calls
-$624M
Net Calls Change
+$552M
Name Holding Trade Value Shares
Change
Change in
Stake
NIM
301
Northeast Investment Management
Massachusetts
$20.9M +$541K +6,955 +3%
Citadel Advisors
302
Citadel Advisors
Florida
$20.9M -$47.7M -612,456 -71%
SMDAM
303
Sumitomo Mitsui DS Asset Management
Japan
$20.8M -$3.13M -40,233 -14%
GG
304
Gofen & Glossberg
Illinois
$20.8M +$109K +1,399 +0.6%
RHBC
305
R.H. Bluestein & Co
Michigan
$20.7M +$2.7M +34,664 +16%
NPPM
306
North Point Portfolio Managers
Ohio
$20.7M +$83.2K +1,069 +0.4%
QBFM
307
QS Batterymarch Financial Management
New York
$20.6M -$5.06M -64,972 -21%
LPL Financial
308
LPL Financial
California
$20.6M +$101K +1,303 +0.5%
WI
309
Wafra Inc
New York
$20.5M -$1.06M -13,650 -5%
BC
310
Bartlett & Co
Ohio
$20.5M +$2.85M +36,580 +17%
LCM
311
Lomas Capital Management
New York
$20.4M +$19.2M +246,490 New
DILH
312
Dai-ichi Life Holdings
Japan
$20.4M -$3.65M -46,863 -16%
Lord, Abbett & Co
313
Lord, Abbett & Co
New Jersey
$20.4M -$137M -1,763,998 -88%
FAB
314
First American Bank
Illinois
$20.3M -$166K -2,135 -0.9%
CIM
315
Contravisory Investment Management
Massachusetts
$20.3M -$1.74M -22,361 -8%
TAM
316
Trillium Asset Management
Massachusetts
$20.2M +$1.37M +17,661 +8%
TMAM
317
Tokio Marine Asset Management
Japan
$20.2M -$1.94M -24,877 -9%
BPBT
318
Boston Private Bank & Trust
Massachusetts
$20.1M +$247K +3,177 +1%
BCM
319
Bridgeway Capital Management
Texas
$20.1M -$208K -2,675 -1%
CGI
320
CI Global Investments
California
$19.9M -$8.17M -105,000 -30%
DCM
321
Dupont Capital Management
Delaware
$19.6M +$15.7M +201,823 +586%
WA
322
Whitebox Advisors
Minnesota
$19.5M +$18.3M +234,747 New
BPC
323
Banque Pictet & Cie
Switzerland
$18.9M +$9.1M +116,959 +105%
RCM
324
Riverhead Capital Management
Delaware
$18.8M +$9.33M +119,851 +112%
CFB
325
Cullen/Frost Bankers
Texas
$18.8M +$144K +1,856 +0.8%

GILD Hedge Fund Activity: Q2 2014 in Review

1,263 of the 3,481 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q2 2014, worth a combined $116B — down 0.49% from $116B a quarter earlier.

Buyers outnumbered sellers: 163 funds opened new GILD positions and 83 closed out — a net gain of 80 holders — while 527 added to existing stakes and 461 trimmed.

The largest buyer was Capital Research Global Investors, adding an estimated $1.16B. The largest seller was BNP Paribas Financial Markets, cutting an estimated $3.85B.

  • 1,263 institutional investors held Gilead Sciences (GILD) as of Q2 2014, up from 1,189 in Q1 2014.
  • Funds reported $116B of Gilead Sciences stock for Q2 2014, down 0.49% quarter-over-quarter.
  • 163 funds opened new Gilead Sciences positions in Q2 2014 and 83 closed out, a net change of +80 holders.
  • The largest Gilead Sciences buyer in Q2 2014 was Capital Research Global Investors, an estimated $1.16B added.
  • The largest Gilead Sciences seller in Q2 2014 was BNP Paribas Financial Markets, an estimated $3.85B sold.

Based on aggregated 13F filings for Q2 2014.